Portal de Periódicos da CAPES

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model

2023; Elsevier BV; Volume: 9; Issue: 6 Linguagem: Inglês

10.1016/j.heliyon.2023.e16664

2405-8440

Cécile Hérate, Romain Marlin, Franck Touret, Nathalie Dereuddre‐Bosquet, Flora Donati, Francis Relouzat, Laura Junges, Mathilde Galhaut, Océane Dehan, Quentin Sconosciuti, Antoine Nougairède, Xavier de Lamballerie, Sylvie van der Werf, Roger Le Grand,

SARS-CoV-2 detection and testing

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both